Latest news with #Elsevier
Techday NZ
7 days ago
- Health
- Techday NZ
Elsevier unveils Embase AI to transform biomedical data research
Elsevier has launched Embase AI, a generative artificial intelligence tool aimed at changing how researchers and medical professionals access and analyse biomedical data. The tool has been developed in collaboration with the scientific community and is built upon Elsevier's Embase platform, a widely used biomedical literature database. According to feedback from beta users, Embase AI can reduce the time spent on reviewing biomedical data by as much as 50%. Natural language features Among its central features, Embase AI allows users to conduct searches in natural language, ranging from basic to complex scientific queries. The system then provides instant summaries of the relevant data and research insights. Each answer comes with a list of linked citations to assist users in evaluating the evidence and meeting expectations around medical regulation. Unlike some other AI solutions that may obscure data provenance, Embase AI delivers transparency by presenting citations and ensuring that the underlying sources can be cross-checked. The database underpinning Embase AI is updated continuously and includes records such as adverse drug reaction reports, peer-reviewed journal articles, and around 500,000 clinical trial listings from This makes it suitable for a range of professional needs, including medical research, pharmacovigilance, regulatory submissions and the generation of market insights. Expanded access By enabling natural language querying, Embase AI seeks to open up biomedical data analysis to a broader group of users, including those who may lack advanced technical experience with literature reviews. Information is summarised for swift consumption while retaining the supporting references, limiting the likelihood that important findings go overlooked. The AI solution uses a dual-stage ranking system to generate summary responses with inline citations. This approach is designed to ensure transparency and help users trust the results. A human-curated hierarchy of medical concepts and their synonyms underpins the system, contributing to the precision and transparency of its outputs. Embase AI's records are updated daily, and its architecture allows the tool to function in real time, searching the platform's full content including peer-reviewed research, clinical trials, preprints and conference abstracts. Security and privacy Elsevier has stated that Embase AI was developed in accordance with its Responsible AI Principles and Privacy Principles to ensure robust data privacy and security. The company notes that the model's use of third-party large language models (LLMs) is private, with no user information being stored or employed to train public versions of these models. All data is retained solely within Elsevier's protected environment. "Embase AI is changing the way researchers and other users go about solving problems and helps them save valuable time searching for answers, digesting information, and avoiding the risk of missing valuable insights. Every user should have access to trusted research tools that help them advance human progress, and we remain committed to working in partnership with scientists across academia, life sciences and other innovative industries to ensure that our solutions address their needs. We know that our users seek solutions that they can trust, and we built Embase AI in a way that ensures transparency, explainability and accuracy." This statement was made by Mirit Eldor, Managing Director, Life Sciences at Elsevier. Ongoing development Embase AI is the latest addition to Elsevier's suite of products aimed at supporting the biomedical research community by facilitating discovery, analysis, and evidence synthesis using responsibly developed AI tools underpinned by trusted content. The platform is designed to meet the needs of professionals in roles such as research and development, medical affairs, academic research, knowledge management, and medical education.
Scoop
24-06-2025
- Business
- Scoop
How Academics Are Pushing Back On The For-Profit Academic Publishing Industry
According to the independent news organization the Conversation, five publishing houses control about half the global academic publishing industry's market share. Relx, the parent company of the 'biggest player in this business,' Elsevier, reaped a profit margin of almost 40 percent in 2023, 'rivalling tech giants such as Microsoft and Google,' pointed out the March 2025 article. 'Many of the most trusted and prestigious research journals are owned by commercial publishers,' the Conversation noted. 'For example, the Lancet is owned by Elsevier.' In 2024, the editorial board for the paleoanthropology bulletin Journal of Human Evolution (JHE) collectively resigned. Besides deficient copyediting and unethical use of AI, which resulted in what the journal Science calls 'scientifically significant errors,' the board accused its publisher, Elsevier, of overcharging. High article processing charges (APCs) are common in the for-profit academic publishing industry. The 2021 paper 'Equitable Open Access Publishing: Changing the Financial Power Dynamics in Academia' notes that high APCs 'exacerbate disparities between funded and unfunded researchers.' 'Traditional academic publishers exploit scholars in several ways,' says Denis Bourguet, co-founder of Peer Community In (PCI), a nonprofit platform that offers 'peer review, recommendation, and publication of scientific articles in open access (OA) for free,' according to its website. Bourguet says common practices within the traditional academic publishing model commodify scholarly knowledge, treating it not as a public good but as a resource to extract profit. 'Researchers produce articles, conduct peer reviews, and often serve as editors, typically without pay, while publishers profit by charging high fees to both authors and readers. With this model, authors must pay substantial article processing charges to publish in open access. Yet, in some journals, since some articles remain behind paywalls, universities and libraries must pay subscriptions to give their members free access to the full content of these journals,' adds Bourguet. PCI co-founder Thomas Guillemaud notes that costly paywalls make 'access difficult for researchers without institutional support, especially in low-income regions.' He adds that the 'pay-to-read or pay-to-publish model encourages researchers to focus on publishing in prestigious journals for career advancement, sometimes at the expense of research quality. This 'prestige economy' can distort scientific priorities and integrity. Pressures to publish in prestigious journals contribute to issues like irreproducible results, publication bias, and even scientific misconduct.' According to a 2025 report in the Proceedings of the National Academy of Sciences, despite major advances such as the antiretroviral therapy and vaccines during the pandemic, science 'faces challenges due to the incentive systems,' with for-profit publishers trying to 'capitalize on unpaid reviewers and [charging] high fees for sharing and accessing knowledge.' PCI is one of many academic-led initiatives challenging the dominance of for-profit publishers and, as Guillemaud puts it, 'reshaping scholarly communication.' Lifecycle Journal, for instance, does not charge its authors or readers. It 'is a new transparent model of scholarly communication that aims to put publishing and evaluation in the control of the scholarly community itself,' its website states. Similarly, SciPost, 'the home of genuine open publishing,' claims, 'We don't charge authors, we don't charge readers, we don't send bills to anybody for our services, and we certainly don't make any profit; we are an academic community service surviving on support from organizations that benefit from our activities. Said otherwise, our system is academia's antidote to APCs.' The Free Journal Network curates and promotes Diamond OA journals that charge neither authors nor readers, ensuring adherence to fair open access principles and supporting a growing ecosystem of scholar-led publications. The French nonprofit publishing platform Centre Mersenne 'endeavors to fight research output's privatization and outrageous profit-making out of the scientific commons,' according to its site. Its 'agenda is to support Diamond Open Access or Gold OA without APC (no fees required to read nor to publish).' Diamond and Gold are two of many OA publishing models. Journals that use the Diamond Open Access model do not charge fees for readers or authors. Funding comes from academic institutions, research funders, philanthropists, governments, advertisers, and nonprofit organizations. Meanwhile, the Medical College of Wisconsin describes the Green OA model as 'the practice of placing a version of an author's manuscript into a repository, making it freely accessible for everyone… No article processing charges are paid.' The Georgia State University Library also outlines various types of OA models. Besides adopting the OA model, academics are countering for-profit academic journals by publishing academic-led journals, putting pressure on publishers to lower their fees, renegotiating contracts, and forming consortia. PCI embraces the Diamond OA model. Its support officer, Barbara Class, explains that its Peer Community Journal is free for authors and readers. This 'removes financial barriers imposed by article processing charges or subscription fees common in for-profit publishing. In addition, PCI publishes peer reviews and editorial decisions openly, promoting transparency and accountability in contrast to the often-opaque evaluation processes performed by for-profit journals.' Class adds, 'PCI focuses on the intrinsic value and quality of research rather than journal-based metrics.' Guillemaud says PCI is sustained through a 'community-driven funding model based primarily on small, recurring public subsidies from universities, libraries, and research institutions. These institutions contribute annually on a pay-what-you-can basis… allowing broad participation regardless of size or budget. This stable and diversified funding base enables PCI to cover its operational costs without large private donors or charging fees to authors or readers.' Author Bio: Damon Orion is a writer, journalist, musician, artist, and teacher in Santa Cruz, California. His work has appeared in Revolver, Guitar World, Spirituality + Health, Classic Rock, and other publications. Read more of his work at
Yahoo
21-06-2025
- Business
- Yahoo
RELX PLC (RELX): A Bull Case Theory
We came across a bullish thesis on RELX PLC (RELX) on FluentInQuality's Substack. In this article, we will summarize the bulls' thesis on RELX. RELX PLC (RELX)'s share was trading at $52.97 as of 10th June. RELX 's trailing and forward P/E were 38.02 and 29.94 respectively according to Yahoo Finance. A data analyst using cutting-edge analytics to accurately interpret complex sets of data. RELX Plc (REL) has quietly transformed itself from a traditional publishing house into an indispensable data and analytics powerhouse embedded in the workflows of scientists, lawyers, regulators, and financial professionals. Its crown jewels—Elsevier, LexisNexis, ICIS, and FlightGlobal—don't chase headlines; they provide deeply validated, mission-critical information that professionals rely on daily. RELX doesn't sell news or trend-driven content—it sells trust, insight, and operational confidence. Whether diagnosing a rare disease or modeling global trade flows, its tools are often the first—and only—stop for users. This embedded relevance creates a business model with powerful economics: subscription-based revenue, high renewal rates, low marginal costs, and 30 %+ operating margins. Once inside an institution, RELX is rarely replaced. Behind its steady exterior, RELX is a stealth acquirer, layering AI, predictive analytics, and risk-scoring capabilities through targeted tuck-ins and bolt-ons that enrich its data ecosystems. These acquisitions are rarely flashy but sharply focused, reinforcing pricing power and customer retention across its segments. Each division amplifies the others—legal workflows benefit from real-time risk data, compliance platforms pull from dynamic regulatory feeds, and scientific research is elevated through AI-driven insights. The result isn't a fragmented portfolio but a deeply integrated web of solutions that are difficult to replicate or displace. With mid-single-digit organic growth, high-margin reinvestment, and an unyielding grip on high-stakes workflows, RELX stands out as a quiet compounder. It doesn't ride hype cycles or make splashy pivots—it wins by embedding itself where complexity, regulation, and trust converge. In a world obsessed with noise, RELX thrives on necessity. Previously, we covered a bullish thesis on SAP SE (SAP) by FluentInQuality, which framed the company as foundational infrastructure for global business, quietly evolving into a cloud-first, AI-augmented platform with remarkable customer stickiness and operational leverage. The stock price has appreciated by roughly 4% since our coverage. FluentInQuality's thesis on RELX PLC (RELX) echoes this theme of indispensable enterprise software; RELX operates behind the scenes, embedding itself deeply in mission-critical workflows across legal, scientific, and regulatory domains. Both companies are quiet compounders thriving on necessity, not novelty, with RELX paralleling SAP's durability through high-margin, subscription-based models and integrated data ecosystems that are nearly impossible to replace. RELX PLC (RELX) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 18 hedge fund portfolios held RELX at the end of the first quarter which was 16 in the previous quarter. While we acknowledge the risk and potential of RELX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Yahoo
21-06-2025
- Business
- Yahoo
RELX PLC (RELX): A Bull Case Theory
We came across a bullish thesis on RELX PLC (RELX) on FluentInQuality's Substack. In this article, we will summarize the bulls' thesis on RELX. RELX PLC (RELX)'s share was trading at $52.97 as of 10th June. RELX 's trailing and forward P/E were 38.02 and 29.94 respectively according to Yahoo Finance. A data analyst using cutting-edge analytics to accurately interpret complex sets of data. RELX Plc (REL) has quietly transformed itself from a traditional publishing house into an indispensable data and analytics powerhouse embedded in the workflows of scientists, lawyers, regulators, and financial professionals. Its crown jewels—Elsevier, LexisNexis, ICIS, and FlightGlobal—don't chase headlines; they provide deeply validated, mission-critical information that professionals rely on daily. RELX doesn't sell news or trend-driven content—it sells trust, insight, and operational confidence. Whether diagnosing a rare disease or modeling global trade flows, its tools are often the first—and only—stop for users. This embedded relevance creates a business model with powerful economics: subscription-based revenue, high renewal rates, low marginal costs, and 30 %+ operating margins. Once inside an institution, RELX is rarely replaced. Behind its steady exterior, RELX is a stealth acquirer, layering AI, predictive analytics, and risk-scoring capabilities through targeted tuck-ins and bolt-ons that enrich its data ecosystems. These acquisitions are rarely flashy but sharply focused, reinforcing pricing power and customer retention across its segments. Each division amplifies the others—legal workflows benefit from real-time risk data, compliance platforms pull from dynamic regulatory feeds, and scientific research is elevated through AI-driven insights. The result isn't a fragmented portfolio but a deeply integrated web of solutions that are difficult to replicate or displace. With mid-single-digit organic growth, high-margin reinvestment, and an unyielding grip on high-stakes workflows, RELX stands out as a quiet compounder. It doesn't ride hype cycles or make splashy pivots—it wins by embedding itself where complexity, regulation, and trust converge. In a world obsessed with noise, RELX thrives on necessity. Previously, we covered a bullish thesis on SAP SE (SAP) by FluentInQuality, which framed the company as foundational infrastructure for global business, quietly evolving into a cloud-first, AI-augmented platform with remarkable customer stickiness and operational leverage. The stock price has appreciated by roughly 4% since our coverage. FluentInQuality's thesis on RELX PLC (RELX) echoes this theme of indispensable enterprise software; RELX operates behind the scenes, embedding itself deeply in mission-critical workflows across legal, scientific, and regulatory domains. Both companies are quiet compounders thriving on necessity, not novelty, with RELX paralleling SAP's durability through high-margin, subscription-based models and integrated data ecosystems that are nearly impossible to replace. RELX PLC (RELX) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 18 hedge fund portfolios held RELX at the end of the first quarter which was 16 in the previous quarter. While we acknowledge the risk and potential of RELX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Associated Press
18-06-2025
- Health
- Associated Press
Hong Kong Baptist University and Elsevier Report Highlights Global Expansion of Chinese Medicine Research, Urges Standardised Frameworks for Broader Integration
ISTANBUL, TURKEY - Media OutReach Newswire - 18 June 2025 – The report 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine' released today by Hong Kong Baptist University (HKBU) and Elsevier, reveals the growing impact of Chinese Medicine research on global healthcare and modern health challenges. In this context, 'Chinese Medicine research' encompasses not only clinical practice, but also basic and translational science, AI-driven systems medicine, and the network pharmacology of herbal formulas. This first bibliometric analysis of Chinese Medicine research from 2014 to 2023 highlights the field's rapid growth, interdisciplinarity, and societal impact on Digital Health and Systems Medicine. HKBU and Elsevier launched a new report 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine', highlighting the growing global impact of Chinese Medicine research in diversified healthcare solutions. Key findings from the report include: Bridging a global integration gap Chinese Medicine's mainstream integration lacks a global, transparent, evidence-based framework. To elevate its scientific profile, key strategies include developing internationally accepted clinical guidelines through expert consensus, enhancing trial reporting standards to improve research quality, and fostering interdisciplinary, cross-regional collaboration to drive innovation and systemic impact. ''Evolving Legacy' demonstrates how Chinese Medicine research has matured into a global, evidence-informed field,' said Professor Lyu Aiping, Vice-President (Research & Development), HKBU, and a leading expert in Chinese Medicine. 'We envision a future where data science and AI illuminate what Chinese Medicine research has long intimated, providing deeper insights into health classifications and compound interventions. The next frontier is using Chinese Medicine research to uncover insights possibly overlooked in Digital Health and Systems Medicine, strengthening their scientific foundation and impact.' 'This report offers unprecedented insights into Chinese Medicine's evolving scientific landscape,' added Basak Candemir, Business Development Director, Analytical and Data Services, Elsevier. 'It illuminates the growing global impact of Chinese Medicine research and its role in diversified healthcare solutions, making a vital step towards bridging traditional knowledge with modern validation for the benefit of global health.' The report was developed using Elsevier's bibliometric tools, Scopus and SciVal, based on a comprehensive dataset and case studies compiled in collaboration with HKBU Chinese Medicine research experts. The report can be accessed on Hashtag: #HKBU The issuer is solely responsible for the content of this announcement.
